On Tuesday, Zimmer Biomet Holdings got a positive adjustment to its Relative Strength (RS) Rating, from 62 to 74.
This unique rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks tend to have an RS Rating of over 80 as they launch their largest climbs. See if Zimmer Biomet Holdings can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
Zimmer Biomet Holdings is working on a consolidation with a 133.90 entry. See if it can break out in heavy volume.
The company showed 5% earnings growth in its most recent report, while sales growth came in at 4%.
The company holds the No. 22 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
